Approved an investment of Rupees 10 million in the Equity Shares of Advanced Nutrazyme Private Limited, an existing Wholly Owned Subsidiary.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board meeting on August 2, 2025 approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Consolidated revenue from operations grew to ₹1,859.14 million, up about 20% from ₹1,545.24 million in the same quarter last year. Consolidated net profit rose to ₹404.40 million (from ₹349.76 million), with EPS at ₹3.57 versus ₹3.05 earlier. The board also approved a ₹10 million cash investment in Advanced Nutrazyme Private Limited, a wholly owned subsidiary incorporated on July 4, 2025, which will handle the company's nutrition and wellness product range. Statutory auditor MSKA & Associates issued an unmodified (clean) limited review conclusion on both standalone and consolidated results. An interim dividend of ₹4 per share was paid during the quarter, and a final dividend of ₹1.20 per share for FY25 was approved by shareholders.
The ~20% year-on-year revenue growth is a positive signal of business momentum, though profit growth of ~15% trailed revenue, suggesting some margin pressure. The ₹10 million subsidiary investment is small and unlikely to move the stock, but it shows expansion into the nutrition and wellness segment. The clean auditor opinion and dividend payout should provide comfort to shareholders.